智通财经网·2026-01-08 07:44Core Viewpoint - JD Health has entered into a deep collaboration with local innovative pharmaceutical company Kaiji Xincheng Biopharmaceutical Technology Co., Ltd. to enhance the treatment options for chronic hepatitis B patients in China [1][2]. Group 1: Partnership and Product Launch - The collaboration aims to integrate JD Health's strengths in medical services and instant retail to support clinical cure goals for chronic hepatitis B patients [1]. - The first launch of the innovative drug, Mesylate Prefofovir Tablets (brand name: Xinshumu®), and Zinc-Selenium Multivitamin Soft Capsules (brand name: Kaimumu®) will be exclusive to JD Health's platform [1][2]. - Mesylate Prefofovir Tablets are designed for adult chronic hepatitis B treatment and have received significant support from national major new drug creation technology projects [1]. Group 2: Clinical Efficacy and Product Features - Phase III clinical trial results indicate that the drug effectively suppresses the virus more powerfully and durably, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL compared to the control group (P<0.05) [1]. - The Zinc-Selenium Multivitamin Soft Capsules are formulated to support liver health and are rich in various vitamins and minerals, designed for easy absorption [2]. Group 3: Service Integration and Future Plans - JD Health will leverage its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to create a comprehensive service loop for the new drugs, ensuring rapid accessibility for patients [2]. - The company plans to continue deepening strategic collaboration with Kaiji Xincheng to optimize patient service experiences and enhance the overall efficiency and quality of the pharmaceutical supply chain [2][3]. - JD Health aims to contribute to the "Healthy China 2030" strategic goals by improving the accessibility of innovative drugs through partnerships with global pharmaceutical companies [3].